References
- Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004;76:205–13.
- Bennett I, Forssen U, Enger C, Nelson J. Risk of thromboembolic events among patients with chronic idiopathic thrombocytopenic purpura (ITP). Haematologica 2008;93:Abstract 0307.
- Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland A, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia (ITP) in the United Kingdom General Practice Research Database. Haematologica 2010;95:1167–75.
- Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, Sørensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011;152:360–2.
- Bussel JB, Zhang J, Tang S, McIntosh J, Kuter DJ. A randomized, double-blind, placebo-controlled Phase II trial on the efficacy, safety and tolerability of E5501 (AKR501) in subjects with chronic immune thrombocytopenia (ITP). Blood 2010;116:Abstract 71.
- Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008;141:545–8.
- Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393–402.
- Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935–43.
- Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114.
- Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889–99.
- Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714–21.
- De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002;87:1095–108.
- Jenkins PV, Rawley O, Smith OP, O’Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012;157:653–63.
- Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113:636–42.
- Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537–45.
- Salazar-Sanchez L. Geographic and ethnic differences in the prevalence of thrombophilia. In: Tranquilli A, editor. Thrombophilia. ISBN: 978-953-307-872-4, InTech, DOI: 10.5772/28405. 2011. Available from: http://www.intechopen.com/books/thrombophilia/geographic-and-ethnic-differences-in-the-prevalence-of-thrombophilia. Accessed 31 March 2014.